ERBB2 and breast carcinoma: In agreement with these data, clinical evidence shows that over-expression of both EGFR and HER2, which is found in 50% and 30% of breast cancers, respectively, correlates with a decreased sensitivity to endocrine therapy and with poor patient prognosis (Pietras, 2003).